Thérapeutique : les anticorps anti-CD 20 monoclonaux (rituximab)
Rapporté par
Thomas De Broucker (St-Denis) d'après la communication :
Safety, pharmacodynamics, and activity of rituximab in patients with relapsing-remitting multiple sclerosis: a phase I, multicentre, open-label clinical trial
A. Bar-Or, P. Calabresi, D.L. Arnold, C. Markowitz, S. Shafer, L. Kasper, E. Waubant, S. Gazda, R. Fox, M. Panzara, N. Sarkar, S. Agarwal, C. Smith (Montreal, CAN; Baltimore, USA; Philadelphia, Vero Beach, Lebanon, San Francisco, San Antonio, Cleveland, Cambridge, South San Francisco, USA)